Tags

Type your tag names separated by a space and hit enter

Insulin resistance and metformin in polycystic ovary syndrome.
Eur J Obstet Gynecol Reprod Biol 2004; 115(2):125-33EJ

Abstract

Polycystic ovary syndrome (PCOS) is a heterogeneous disorder with widespread systemic manifestations affecting 5-10% of women of reproductive age. The accompanying insulin resistance and hypeinsulinemia mark this syndrome as a prediabetic state, with high incidence of impaired glucose tolerance, gestational diabetes, and overt diabetes. Other metabolic and biochemical changes, such as hypertension and dyslipidemia, increase the risk of cardiovascular disease. Fertility may also be impaired due to anovulation, impaired implantation, and higher rates of spontaneous abortions. All of these effects may also be related to hyperinsulinemia. Metformin, as insulin-sensitizing drug, is being evaluated for its potential long-term disease-modifying effect, such as prevention of diabetes. Its use may also help restore spontaneous ovulation and improve menstrual cyclicity, improve the success rate of induction of ovulation with clomiphene citrate and FSH, and decrease the high rate of ovarian hyperstimulation and early pregnancy loss. Nevertheless, these new exiting potential benefits of metformin should be evaluated in large randomized controlled studies, and clinicians must counsel women appropriately before the initiation of metformin therapy.

Authors+Show Affiliations

Department of Obstetrics and Gynecology, Rabin Medical Center, Campus Beilinson, Petah-Tikva, Israel. yudavi@inter.net.ilNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

15262344

Citation

Ben-Haroush, Avi, et al. "Insulin Resistance and Metformin in Polycystic Ovary Syndrome." European Journal of Obstetrics, Gynecology, and Reproductive Biology, vol. 115, no. 2, 2004, pp. 125-33.
Ben-Haroush A, Yogev Y, Fisch B. Insulin resistance and metformin in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2004;115(2):125-33.
Ben-Haroush, A., Yogev, Y., & Fisch, B. (2004). Insulin resistance and metformin in polycystic ovary syndrome. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 115(2), pp. 125-33.
Ben-Haroush A, Yogev Y, Fisch B. Insulin Resistance and Metformin in Polycystic Ovary Syndrome. Eur J Obstet Gynecol Reprod Biol. 2004 Aug 10;115(2):125-33. PubMed PMID: 15262344.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Insulin resistance and metformin in polycystic ovary syndrome. AU - Ben-Haroush,Avi, AU - Yogev,Yariv, AU - Fisch,Benjamin, PY - 2003/04/29/received PY - 2003/10/28/revised PY - 2003/11/12/accepted PY - 2004/7/21/pubmed PY - 2004/12/16/medline PY - 2004/7/21/entrez SP - 125 EP - 33 JF - European journal of obstetrics, gynecology, and reproductive biology JO - Eur. J. Obstet. Gynecol. Reprod. Biol. VL - 115 IS - 2 N2 - Polycystic ovary syndrome (PCOS) is a heterogeneous disorder with widespread systemic manifestations affecting 5-10% of women of reproductive age. The accompanying insulin resistance and hypeinsulinemia mark this syndrome as a prediabetic state, with high incidence of impaired glucose tolerance, gestational diabetes, and overt diabetes. Other metabolic and biochemical changes, such as hypertension and dyslipidemia, increase the risk of cardiovascular disease. Fertility may also be impaired due to anovulation, impaired implantation, and higher rates of spontaneous abortions. All of these effects may also be related to hyperinsulinemia. Metformin, as insulin-sensitizing drug, is being evaluated for its potential long-term disease-modifying effect, such as prevention of diabetes. Its use may also help restore spontaneous ovulation and improve menstrual cyclicity, improve the success rate of induction of ovulation with clomiphene citrate and FSH, and decrease the high rate of ovarian hyperstimulation and early pregnancy loss. Nevertheless, these new exiting potential benefits of metformin should be evaluated in large randomized controlled studies, and clinicians must counsel women appropriately before the initiation of metformin therapy. SN - 0301-2115 UR - https://www.unboundmedicine.com/medline/citation/15262344/Insulin_resistance_and_metformin_in_polycystic_ovary_syndrome_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0301211504000612 DB - PRIME DP - Unbound Medicine ER -